Target intelligence / Profile preview

Dihydrofolate reductase (DHFR)

Target
DHFR
Molecular classification
Enzyme, Oxidoreductase
01

Overview

The term "Folate metabolism enzyme" is not a specific canonical name but refers to a group of enzymes involved in the cellular processing of folates. The most clinically relevant and commonly targeted member is Dihydrofolate reductase (DHFR). DHFR catalyzes the reduction of dihydrofolic acid to tetrahydrofolic acid using NADPH as an electron donor—a critical step for regenerating active folates required for one-carbon transfer reactions in nucleotide biosynthesis and amino acid interconversion[1][3][4]. Inhibition of DHFR disrupts DNA synthesis, repair, and methylation processes essential for rapidly dividing cells; this underlies its role as a major target in cancer chemotherapy by agents such as methotrexate[1][2]. Other enzymes within the folate pathway include serine hydroxymethyltransferase, methionine synthase, glycinamide ribonucleotide transformylase, among others—each contributing to nucleotide or amino acid biosynthesis or methylation cycles[2][3]. Note: The query "Folate metabolism enzyme" is too broad; it should be mapped specifically to "Dihydrofolate reductase" when referring to drug targets unless context indicates another specific enzyme. If more detail on other individual enzymes is needed (e.g., methionine synthase), those should be specified.

Other names
Folate metabolism enzymeFolate pathway enzymeTetrahydrofolate synthase (rare)Dihydrofolate reductase (DHFR) family enzymes
02

Mechanism of action

Competitive inhibition of dihydrofolate reductase to block tetrahydrofolate production, thereby inhibiting DNA synthesis and cell division[1][2].

03

Biological functions

DNA synthesis and repairAmino acid metabolismMethylation reactions (epigenetic regulation)
04

Disease associations

CancerMegaloblastic anemiaCardiovascular disease (via homocysteine metabolism)
05

Safety considerations

Bone marrow suppression with antifolate drugs[1]Gastrointestinal toxicity with antifolate drugs[1]
06

Interacting drugs

Methotrexate

2 more in the full profile.

07

Biomarkers

Homocysteine levels (for folate status and cardiovascular risk)[3][5]

Beyond the preview

Go deeper on Dihydrofolate reductase (DHFR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dihydrofolate reductase (DHFR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call